Myrexis (Myrexis) Additional Paid-In Capital

: $129.31 Mil(As of Jun. 2013) 中文

View and export this data going back to 2013. Start your Free Trial

Myrexis's quarterly additional paid-in capital declined from Dec. 2012 ($207.06 Mil) to Mar. 2013 ($129.31 Mil) but then stayed the same from Mar. 2013 ($129.31 Mil) to Jun. 2013 ($129.31 Mil).

Myrexis's annual additional paid-in capital increased from Jun. 2011 ($203.30 Mil) to Jun. 2012 ($205.97 Mil) but then declined from Jun. 2012 ($205.97 Mil) to Jun. 2013 ($129.31 Mil).

Myrexis Additional Paid-In Capital Historical Data

The historical data trend for Myrexis's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Annual Data

Trend

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Additional Paid-In Capital

188.40

196.53

203.30

205.97

129.31

Myrexis Quarterly Data
	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13
Additional Paid-In Capital																205.97	206.17	207.06	129.31	129.31

Myrexis Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Myrexis Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Myrexis's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Myrexis (Myrexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020

Website

http://www.myrexis.com

Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Executives

Xstelos Corp.	10 percent owner	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe	director	1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper	director	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman	director, officer: Chairman, President and CEO	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska	director, officer: Chief Operating Officer	749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer	director, officer: President and CEO	C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden	director, officer: President and CEO	320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie	officer: Chief Operating Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines

From GuruFocus

Myriad Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 09-13-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-16-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-17-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-09-2011